Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
Amicus Therapeutics (Nasdaq: FOLD) has announced its participation in the 29th Annual Congress of the World Muscle Society, taking place from October 8-12, 2024, in Prague, Czechia. The company will present three posters focusing on its Pompe disease development program:
1. Cipaglucosidase alfa + miglustat in late-onset Pompe disease: Two non-ambulatory patients switching from high-dose, high-frequency alglucosidase alfa
2. Post-baseline outcomes of the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in late-onset Pompe disease
3. Miglustat: a first-in-class enzyme stabilizer for late-onset Pompe disease
All posters will be presented on Friday, October 11, from 3:45 – 4:45 p.m. CET in the Forum Hall of The Prague Congress Centre.
Amicus Therapeutics (Nasdaq: FOLD) ha annunciato la sua partecipazione al 29° Congresso Annuale della World Muscle Society, che si terrà dal 8 al 12 ottobre 2024 a Praga, in Repubblica Ceca. L'azienda presenterà tre poster focalizzati sul suo programma di sviluppo per la malattia di Pompe:
1. Cipaglucosidasi alfa + miglustat nella malattia di Pompe a insorgenza tardiva: Due pazienti non deambulanti che passano da alglucosidasi alfa ad alta dose e alta frequenza
2. Esiti post-baseline del registro del Regno Unito sulla Early Access to Medicines Scheme per cipaglucosidasi alfa più miglustat nella malattia di Pompe a insorgenza tardiva
3. Miglustat: un stabilizzatore enzimatico di prima classe per la malattia di Pompe a insorgenza tardiva
Tutti i poster saranno presentati venerdì 11 ottobre, dalle 15:45 alle 16:45 CET nella Forum Hall del Centro Congressi di Praga.
Amicus Therapeutics (Nasdaq: FOLD) ha anunciado su participación en el 29º Congreso Anual de la World Muscle Society, que se llevará a cabo del 8 al 12 de octubre de 2024 en Praga, Chequia. La empresa presentará tres carteles centrados en su programa de desarrollo para la enfermedad de Pompe:
1. Cipaglucosidasa alfa + miglustat en la enfermedad de Pompe de inicio tardío: Dos pacientes no ambulatorios que cambian de alglucosidasa alfa a alta dosis y alta frecuencia
2. Resultados post-baseline del registro del Reino Unido para el esquema de Acceso Temprano a Medicamentos para cipaglucosidasa alfa más miglustat en la enfermedad de Pompe de inicio tardío
3. Miglustat: un estabilizador enzimático de primera en su clase para la enfermedad de Pompe de inicio tardío
Todos los carteles se presentarán el viernes 11 de octubre, de 15:45 a 16:45 CET en el Forum Hall del Centro de Congresos de Praga.
Amicus Therapeutics (Nasdaq: FOLD)는 2024년 10월 8일부터 12일까지 체코 프라하에서 열리는 제29회 세계 근육 학회 연례 총회에 참여한다고 발표했습니다. 이 회사는 포메병 개발 프로그램에 중점을 둔 세 개의 포스터를 발표할 예정입니다:
1. 지파글루코시다제 알파 + 미글루스타트, 후기 발병 포메병에서: 고용량 고빈도 알글루코시다제 알파에서 전환한 두 명의 비보행 환자
2. 후기 발병 포메병에서 cipaglucosidase alfa와 miglustat에 대한 영국 조기 의약품 접근 프로그램의 기초 이후 결과
3. 미글루스타트: 후기 발병 포메병을 위한 최초의 효소 안정제
모든 포스터는 10월 11일 금요일, CET 오후 3시 45분부터 4시 45분까지 프라하 콘그레스 센터의 포럼 홀에서 발표됩니다.
Amicus Therapeutics (Nasdaq: FOLD) a annoncé sa participation au 29e Congrès Annuel de la World Muscle Society, qui se déroulera du 8 au 12 octobre 2024 à Prague, en République tchèque. L'entreprise présentera trois posters axés sur son programme de développement pour la maladie de Pompe :
1. Cipaglucosidase alfa + miglustat dans la maladie de Pompe à début tardif : Deux patients non ambulants passant d'alglucosidase alfa à forte dose et forte fréquence
2. Résultats post-basal du registre britannique pour l'accès précoce aux médicaments pour cipaglucosidase alfa plus miglustat dans la maladie de Pompe à début tardif
3. Miglustat : un stabilisateur enzymatique de première classe pour la maladie de Pompe à début tardif
Tous les posters seront présentés le vendredi 11 octobre, de 15 h 45 à 16 h 45 CET dans la salle Forum du Centre des congrès de Prague.
Amicus Therapeutics (Nasdaq: FOLD) hat seine Teilnahme am 29. Jahreskongress der World Muscle Society angekündigt, der vom 8. bis 12. Oktober 2024 in Prag, Tschechische Republik, stattfindet. Das Unternehmen wird drei Poster präsentieren, die sich auf sein Entwicklungsprogramm zur Pompe-Krankheit konzentrieren:
1. Cipaglucosidase alfa + Miglustat bei spät einsetzender Pompe-Krankheit: Zwei nicht gehfähige Patienten, die von hochdosierter, hochfrequenter Alglukosidase alfa wechseln
2. Nach-baseline-Ergebnisse des UK Early Access to Medicines Scheme-Registers für Cipaglucosidase alfa plus Miglustat bei spät einsetzender Pompe-Krankheit
3. Miglustat: ein erstklassiger Enzymstabilisator für spät einsetzende Pompe-Krankheit
Alle Poster werden am Freitag, den 11. Oktober, von 15:45 bis 16:45 Uhr CET im Forum-Saal des Prager Kongresszentrums vorgestellt.
- Amicus Therapeutics is presenting three posters at a major industry conference, showcasing its Pompe disease development program
- The company's research focuses on innovative treatments for late-onset Pompe disease, including cipaglucosidase alfa + miglustat and a first-in-class enzyme stabilizer
- None.
PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the 29th Annual Congress of the World Muscle Society being held October 8-12, 2024 in Prague, Czechia.
Poster Session: Pompe Disease
Abstract Title: Cipaglucosidase alfa + miglustat in late-onset Pompe disease: two non-ambulatory patients switching from high-dose, high-frequency alglucosidase alfa (Poster #657P)
- Presenter: Barry J. Byrne, MD, PhD, University of Florida, Gainesville, FL, U.S.A.
- Poster Session: Friday, October 11, 3:45 – 4:45 p.m. CET
- Location: Forum Hall, The Prague Congress Centre
Abstract Title: Post-baseline outcomes of the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in late-onset Pompe disease (Poster #670P)
- Presenter: Mark Roberts, MD, Salford Royal NHS Foundation Trust, Greater Manchester Neurosciences Centre, Manchester, U.K.
- Poster Session: Friday, October 11, 3:45 – 4:45 p.m. CET
- Location: Forum Hall, The Prague Congress Centre
Abstract Title: Miglustat: a first-in-class enzyme stabilizer for late-onset Pompe disease (Poster #671P)
- Presenter: Tahseen Mozaffar, MD, Department of Neurology, University of California, Irvine, CA, U.S.A.
- Poster Session: Friday, October 11, 3:45 – 4:45 p.m. CET
- Location: Forum Hall, The Prague Congress Centre
For more information on the WMS 2024 Annual Congress, please visit www.wms2024.com
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.
CONTACTS:
Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
FAQ
What is Amicus Therapeutics (FOLD) presenting at the World Muscle Society Annual Congress 2024?
When and where is the World Muscle Society Annual Congress 2024 taking place?
What specific treatments for Pompe disease is Amicus Therapeutics (FOLD) showcasing at the conference?
When are the Amicus Therapeutics (FOLD) posters being presented at the World Muscle Society Annual Congress 2024?
